Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Blood

Volumn 120, Issue 13, 2012, Pages 2650-2657

  Ghesquières, Hervé ^a,b   Cartron, Guillaume ^c   Seymour, John Francis ^d   Delfau Larue, Marie Hélène ^e   Offner, Fritz ^f   Soubeyran, Pierre ^g   Perrot, Aurore ^h   Brice, Pauline ⁱ   Bouabdallah, Réda ^j   Sonet, Anne ^k   Dupuis, Jehan ^e   Casasnovas, Olivier ^l   Catalano, John Vincent ^m   Delmer, Alain ⁿ   Jardin, Fabrice ^o   Verney, Aureĺie ^b   Dartigues, Peggy ^p   Salles, Gilles ^b,q  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e HENRI MONDOR HOSPITAL   (France)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m FRANKSTON HOSPITAL   (Australia)

ⁿ REIMS UNIVERSITY HOSPITAL   (France)

^o CENTRE HENRI BECQUEREL   (France)

^p INSTITUT GUSTAVE ROUSSY   (France)

^q HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FC RECEPTOR; FC RECEPTOR 3A; FC RECEPTOR IIA; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FCGR2A GENE; FCGR3A GENE; FEMALE; FOLLICULAR LYMPHOMA; GENE; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 84866863976     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-431825     Document Type: Article

References (48)

1. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007;216-225.
2. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. (Pubitemid 39166497)
3. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010; 92(2):246-254.
4. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169. (Pubitemid 39507628)
5. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007; 109(12):5439-5446. (Pubitemid 46890567)
6. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-1992. (Pubitemid 46972781)
7. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732. (Pubitemid 41742196)
8. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
9. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008; 112(13):4824-4831.
10. Cartron G, Trappe RU, Solal-Celigny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res. 2011;17(1):19-30.
11. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725.
12. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
13. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947. (Pubitemid 46606207)
14. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and eventfree survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16(10):1675-1682. (Pubitemid 41510143)
15. Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007;92(8):1127-1130. (Pubitemid 350144222)
16. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108(8):2720-2725.
17. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51.
18. SNP500 Cancer database. http://snp500cancer.nci.nih.gov/home.cfm. Accessed January 21, 2011.
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
20. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(2):279-284.
21. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109-1114. (Pubitemid 27314146)
22. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005; 304(1-2):88-99. (Pubitemid 41262223)
23. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64(13):4664-4669. (Pubitemid 38856941)
24. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001. (Pubitemid 28496709)
25. Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005;23(6):1096-1102. (Pubitemid 46202264)
26. Muller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14):3276-3284.
27. Jäger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431-1438.
28. Veeramani S, Wang SY, Dahle C, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011;118(12):3347-3349.
29. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27(7):1122-1129.
30. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008; 26(11):1789-1796.
31. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112(12):4452-4457.
32. Boettcher S, Pott C, Ritgen M, Hiddemann W, Unterhalt M, Kneba M. Evidence for FcG receptor IIIA independant rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. Blood. 2004; 104(11):Abstract 590.
33. Lowry L, Pule M, Ardeshna K, et al. FCGR polymorphisms do not influence response to rituximab in asymtomatic, non-bulky follicular lymphoma; results from the intergroup trial of rituximab vs "watch and wait" [abstract]. Ann Oncol. 2011;22(Suppl 4):Abstract 142.
34. Persky DO, Dornan D, Goldman B, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012;97(6):937-942.
35. Pierz KA, Gu S, Lewis ME, et al. Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2010;28(15s):Abstract 8065.
36. Prochazka V, Papajik T, Gazdova J, et al. FcgammaRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma. 2011;58(3):263-270.
37. Weng WK, Weng WK, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma. 2009;50(9):1494-1500.
38. Hatjiharissi E, Hansen M, Santos DD, et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007;7(4):286-290. (Pubitemid 46408193)
39. Lejeune J, Thibault G, Ternant D, et al. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol. 2008;26(33): 5489-5491.
40. Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007;17(4): CD003805.
41. Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010;116(20):4212-4222.
42. Mitrovic Z, Aurer I, Radman I, et al. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica. 2007;92(7):998-999. (Pubitemid 350144253)
43. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699-713.
44. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669. (Pubitemid 38821999)
45. Kahl BS, Williams ME, Hong F, Gascoyne R, Horning SJ. Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT) [abstract]. Blood. 2007;110(11):Abstract 3420.
46. Niwa R, Hatanaka S, Shoji-Hosaka E, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res. 2004;10(18 Pt 1):6248-6255. (Pubitemid 39287533)
47. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126-5132.
48. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 tumor cells. Clin Cancer Res. 2008;14(14):4650-4657.